Nordihydroguaiaretic acid (NDGA)

inflammation redox

Early research only in the markets tracked.

Evidence so far is from animal studies.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (3)

T3 Strong 2016 Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer doi:10.1111/acel.12496
T3 Harrison 2013 Acarbose, 17‐α‐estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males doi:10.1111/acel.12170
T3 Strong 2008 Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice doi:10.1111/j.1474-9726.2008.00414.x